Prodrugs for the treatment of neglected diseases

Molecules

Volumn 13, Issue 3, 2008, Pages 616-677

  Man, Chin Chung ^a   Ferreira, Elizabeth Igne ^b   Santos, Jean Leandro ^a,b   Giarolla, Jeanine ^b   Rando, Daniela Gonçales ^b   Almeida, Adélia Emília ^a   Bosquesi, Priscila Longhin ^a   Menegon, Renato Farina ^a   Blau, Lorena ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b LAPEN Lab de Planejam e Sintese de Quimioterapicos Potencialmente Ativos em Endemias Tropicais   (Brazil)

Author keywords

African trypanosomiasis; American trypanosomisasis; Leishmaniasis; Malaria; Prodrug design; Schistosomiasis; Sickle cell disease; Tropical neglected diseases; Tuberculosis

Indexed keywords

EID: 41649109389     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules13030616     Document Type: Review

References (255)

1. Hotez, P.J.; Molyneux, D.H.; Fenwick, A.; Ottesen, E.; Ehrlich, S.S.; Sachs, J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria, PLoS Med. 2006, 3, e102.
2. Beyrer, C.; Villar, J.D.; Suwanvanichkij, V.; Singh, S.; Baral S.D.; Mills, E.J. Neglected diseases, civil conflicts, and the right to health. Lancet 2007, 370, 619-627.
3. Trouiller, P.; Olliaro, P.; Torreele, E.; Orbinski, J.; Laing, R.; Ford, N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002, 359, 2188-2194.
4. Ehrenberg, J.P.; Ault, S.K. Neglected diseases of neglected populations: thinking to reshape the determinants of health in Latin America and the Caribbean, BMC Public Health 2005, 5, 119-132.
5. Medecins Sans Frontieres. Drugs for Neglected Diseases Initiative: Teaming up to address neglect (12 March, 2003). Accessed from www.accessmed.msf.org in Nov. 2007.
6. Pécoul, B. New drugs for neglected diseases: from pipeline to patients. PloS Med. 2004, 1, 19-22.
7. Pink, R.; Hudson, A.; Mouriès, M.A.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery. Nature Rev. Drug Disc. 2005, 4, 727-740.
8. Lee, H. J.; Cooperwood, J. S.; You, Z.; Ko, D. H... Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch. Pharm. Res. 2002, 25, 111-136.
9. Silva, A.T.A.; Castro, L.F.; Guido, R.V.C.; Chung, M. C.; Ferreira, E.I. Advances in prodrug design. Mini-Rev. Med. Chem. 2005, 5, 893-914.
10. Brener, Z. A descoberta. Mem. Inst. Oswaldo Cruz 1989, 84 (supl II), 1-6.
11. World Health Organization. Chagas Disease: TDR Acessed from http://www.who.int/tdr/diseases/chagas/ in Dec. 2007.
12. Urbina JA. Parasitological cure of Chagas disease: Is it possible? Is it relevant? Mem. Inst. Oswaldo Cruz. 1999, 94, 349-355.
13. Rodrigues-Coura J, de Castro SL. A critical review on Chagas disease chemotherapy.Mem. Inst. Oswaldo Cruz. 2002, 97, 3-24.
14. Urbaniak, M.D.; Tabudravu, J.N.; Msaki, A.; Matera, K.M.; Brenk, R.; Jaspars, M.; Ferguson, M.A.J. Identification of novel inhibitors of UDP-Glc 40-epimerase, a validated drug target for african sleeping sickness. Bioorg. Med. Chem. Lett. 2006, 16, 5744-5747.
15. Nkemngu, N.J.; Grande, R.; Hansell, E.; McKerrow, J.H.; Caffrey, C.R.; Steverding, D. Improved trypanocidal activities of cathepsin L inhibitors. Int. J. Antimicrob. Agents 2003, 22, 155-159.
16. Kuzoe FAS, Perspectives in research on and control of African trypanosomiasis. Ann. Trop. Med. Parasitol. 1991, 85, 33-41.
17. Barrett M.P.The fall and rise of sleeping sickness. Lancet 1999, 353, 1113-1114.
18. World Health Organization. Strategic Direction for Research: Leishmaniosis, 2002.
19. Desjeux, P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Inf. Dis. 2004, 27, 305-318.
20. Szyniarowski, P.; Bettendorff, L.; Schweingruber, M.E. The antitrypanosomal drug melarsoprol competitively inhibits thiamin uptake in mouse neuroblastoma cells. Cell Biol. Toxicol. 2006, 22, 183-187.
21. WHO. The world health report 2004. Changing history. WHO: Geneva, 2004; http://www.who.int/whr/2004/en/index.html (accessed June 12, 2007).
22. Herwaldt, B. L. Miltefosine: The long-awaited therapy for visceral leishmaniasis? N. Engl. J. Med. 1999, 341, 1840-1842.
23. Berman, J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 2003, 16, 397-401.
24. Croft, S.L.; Coombs, G.H. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003, 19, 502-508.
25. Davis, A.J., Murray, H.W., Handman, E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol. 2004, 20, 73-76.
26. Ouellette, M.; Drummelsmith, J.; Papadopoulou, B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Updat. 2004, 7, 257-266.
27. World Health Organization. Global Malaria Programme: Epidemics and Emmergences. http://www.who.int/malaria/epidemicsandemergencies.html. Acessed in December 2007.
28. Biot, C.; Chibale, K. Novel Approaches to Antimalarial Drug Discovery. Infect. Disord. Drug Targets 2006, 6, 173-204.
29. Menezes, C.M.S.; Ferreira, E.I. Modulating agents in resistant malaria. Drug Design Rev. Online 2005, 2, 409-418.
30. World Health Organization. Report of the third global meeting of the partners for parasite control Deworming for Health and Development, 2005. http://www.who.int/wormcontrol Acessed in Dec. 2007.
31. Ribeiro-dos-Santos, G.; Verjovski-Almeida, S.; Leite, L.C.C. Schistosomiasis - a century searching for chemotherapeutic drugs. Parasitol. Res. 2006, 99, 505-521.
32. Murray, J. F. A century of tuberculosis. Am. J. Respir. Crit. Care Med. 2004, 169, 1181-1186.
33. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2007.
34. Bower, D. L.; Lane, H. C.; Fauci, A. S. Immunopathogenesis of the acquired immunodeficiency syndrome. Ann. Intern. Med. 1985, 103, 704-709.
35. Reider, H. L.; Cauthen, G. M.; Comstock, G. W; Snider, D. E. Jr. Epidemiology of tuberculosis in the United States. Epidemiol. Rev. 1989, 11, 79-98.
36. Cardoso, E. M. Multiple drug resistance: a threat for tuberculosis control. Rev. Panam. Salud Publica 2004, 16, 68-73.
37. Elliott, L.; Ashley-Koch, A. E.; De Castro, L.; Jonassaint, J.; Price, J.; Ataga, K. I.; Levesque, M.C.; Weinberg, J.B.; Eckman, J.R.; Orringer, E.P.; Vance, J.M.; Telen, M.J. Genetic polymorphisms associated with priapism in sickle cell disease. Br. J. Haematol. 2007, 137, 262-267.
38. Hebbel, R.P. Special issue of microcirculation: Examination of the vascular pathobiology of sickle cell anemia. Microcirculation 2004, 11, 99-100.
39. Hiran, S. Multiorgan dysfunction syndrome in sickle cell disease. J. Assoc. Physicians India 2005, 53, 19-22.
40. Buchanan, G.R.; Debaun, M.R.; Quinn, C.T.; Steinberg, M.H. Sickle cell disease. Hematology 2004, 1, 35-47.
41. Stuart, M.J.; Nagel, R.L. Sickel-cell disease. Lancet 2004, 364, 1343-1360.
42. Perrine, S.P.; Ginder, G.D.; Faller, D.V.; Dover, G.H.; Ikuta, T.; Witkowska, H.E.; Cai, S.P.; Vichinsky, E.; Olivieri, N.F. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N. Engl. J. Med. 1993, 328, 81-86.
43. Platt, O.S.; Brambilla, D.J.; Rosse, W.F.; Milner, P.F.; Castro, O.; Steinberg, M.H.; Klug, P.P. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 1994, 330, 1639-1644.
44. Powars, D.R.; Weiss, J.N.; Chan, L.S.; Schroeder, W.A. Is there a threshold level of fetal hemoglobin that ameliorates morbidity on sickle cell anaemia? Blood 1983, 63, 921-926.
45. Chung, M-C.; Silva, A. T de A.; Castro, L. F.; Güido, R. V C.; Nassute, J. C.; Ferreira, E. I. Latenciação e formas avançadas de transporte de fármacos. Rev. Bras. Cienc. Farm/Braz. J. Pharm Sci. 2005, 41, 155-179.
46. McKerrow, J.H.; McGrath, M.E.; Engel, J.C. The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitol. Today, 1995, 11, 272-82.
47. Schirmer, R. H.; Müller, J. G.; Krauth-Siegel, L. Disulfide-reductase inhibitors as chemotherapeutic agents: The design of drugs for trypanosomiasis and malaria. Angew. Chem., Int. Ed. Engl. 1995, 34, 141-154
48. Chung, M-C.; Gonçalves, M. F.; Colli, W.; Ferreira, E. I.; Miranda, M. T. Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine. J. Pharm. Sci. 1997, 86, 1127-1131.
49. Bundgaard, H., Ed. Prodrug Design; Elsevier: Amsterdam, 1985
50. Chung, M. C.; Guido, R..V.; Martinelli, T. F.; Goncalves, M. F.; Polli, M. C.; Botelho, K. C.; Varanda, E. A.; Colli, W.; Miranda, M. T.; Ferreira, E. I. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem., 2003, 11, 4779-4783.
51. Trossini, G. H. G.; Ferreira, E. I. ; Menezes, C. M. S. A substrate-specificity evaluation of cruzain by the AM1 semi-empirical method. In: The International Chemical Congress of Pacific Basin Societies - PACIFCHEM 2005, Honolulu, 2005: The International Chemical Congress of Pacific Basin Societies - PACIFCHEM 2005, Abstract Book, 2005.
52. Menezes, C. M. S.; Trossini, G. H. G.; Chung, Mc ; Ferreira, E. I. A semi-empirical evaluation of mutual dipeptide prodrugs of primaquine and nitrofurazone toward antichagasic leads. In: Molecular helminthology & drugs against protozoan parasites. Keystone Symposia - Drugs Against Protozoan Parasites: Target Selection, Structural Biology and Medicinal Chemistry, Silverthone, 2005.
53. Scalea, M. A. L.; Juliao, M. S. S.; Chung, M. C.; Serrano, S. H. P.; Ferreira, E. I. Voltammetric behavior of nitrofurazone and its hydroxymethyl prodrug with potential anti-Chagas' activity. J. Braz. Chem Soc. 2005, 16, 774-782.
54. Gerez de Burgos, N.M.; Burgos, C.; Blanco, A.; Paulone, I.; Segura, E.L. Actividad hidroxiácido-dehidrogenasa en Trypanosoma cruzi. Acta. Physiol. Latinoam. 1976, 26, 10-19.
55. Coronel, C.; Gerez de Burgos, N.M.; Burgos, C.; Blanco, A. Separación y propiedades catalíticas de las izo enzimas de la α-hidroxiácido deshidrogenasa de Trypanosoma cruzi. Medicina (Buenos Aires) 1980, 40, 159-164
56. Coronel, C.E.; Rovai, L.E.; Gerez de Burgos, N.M.; Burgos, C.; Blanco, A. Properties of α-hydroxyacid dehydrogenase isozymes from Trypanosoma cruzi. Mol. Biochem. Parasitol. 1981, 4, 29-38.
57. Montamat, E.E.; Arauzo, S.S.; Blanco, A. Subcellular localization of leucine aminotransferase and a-hydroxiacid dehydrogenase in Trypanosoma cruzi. Mol. Biochem. Parasitol. 1987, 22, 185-193.
58. Elizondo, S.; Chena, M.A, ; Rodríguez-Páez, L. ; Nogueda, B.; Baeza, I.; Wong, C. Inhibition of Trypanosoma cruzi α-Hydroxyacid Dehydrogenase-isozyme II by N-Isopropyl Oxamate and its Effect on Intact Epimastigotes. J. Enz. Inhib. Med. Chem. 2003, 18, 265-271.
59. Aldunate, J.; Repetto, Y.; Letelier, M.E.; Morello, A. The carboxyl esterases of Trypanosoma cruzi epimastigotes. Comp. Biochem. Physiol. 1987, 86, 67-71.
60. Chena, M.A, ; Elizondo, S.; Rodríguez-Páez, L. ; Nogueda, B. ; Baeza, I. ; Wong, C. Trypanocidal activity of N-isopropyl oxamate on cultured epimastigotes and murine trypanosomiasis using different Trypanosoma cruzi strains. J. Enz. Inhib. Med. Chem. 2005, 2, 189-197.
61. Brener, Z. Recent advances in the chemotherapy of Chagas' disease. Mem. Inst. Oswaldo. Cruz. 1984, 79, 149-155.
62. Lanteri, C. A.; Trumpower, B. L.; Tidwell, R. R.; Meshnick,S, R. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemoter. 2004, 48, 3968-3974.
63. Dann, O.; Fick, H.; Pietzner, B.; Walkenhorst, E.; Fernbach, R.; Zeh, D. Trypanocidal diamidine with three isolated ring systems. Justus Liebigs. Ann. Chem. 1975, 160-194.
64. Das, B. P.; Boykin, D. W. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J. Med. Chem. 1977, 20, 531-536.
65. Syrigos, K. N; Epenetos, A. A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. 1999, 19, 605-614.
66. Pratt, R. F.; Faraci, W. S. Direct observation by proton NMR of cephalosporoate intermediates in aqueous solution during the hydrazinolysis and .beta.-lactamase-catalyzed hydrolysis of cephalosporins with 3′ leaving groups: kinetics and equilibria of the 3′ elimination reaction. J. Am. Chem. Soc. 1986, 108, 5328-5333.
67. Nguyen, V. K.; Desmyter, A.; Muyldermans, S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001, 79, 261-296.
68. Lauwereys, M.; Arbabi, Ghahroudi, M.; Desmyter, A.; Kinne, J.; Holzer, W.; De Genst, E.; Wyns, L.; Muyldermans, S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998, 17, 3512-3520.
69. Stijlemans, B.; Conrath, K.; Cortez-Retamozo, V.; Xong, H. V.; Wyns, L.; Senter, P.; Revets, H.; De Baetselier, P.; Muyldermans, S.; Magez, S. Efficient targeting of conserved cryptic epitopes of infectious agents by a single domain antibodies. J. Biol. Chem. 2004, 279, 1256-1261.
70. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robison, G.; Hamers, C.; Songa, E. B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature. 1993, 363, 446-448.
71. Van Meirvenne, N.; Maginus, E.; Janssens, P. G. The effect of normal human serum on trypanosomes of distinct antigenic type (ETat 1 to 12) isolated from a strain of Trypanosoma brucei rhodesiense. Ann. Soc. Belg. Med. Trop. 1976, 56, 55-63.
72. Vanhamme, L; Pays, E. The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness. Int. J. Parasitol. 2004, 34, 887-898.
73. Vanhamme, L.; Paturiaux-Hanocq, F.; Poelvoorde, P.; Nolan, D. P.; Lins, L.; Abbeele, J. V. D.; Pays, A.; Tebabi, P.; Xong, H. V.; Jacquet, A.; Moguilevsky, N.; Dieu, M.; Kane, J. P.; De Baetselier, P.; Brasseur, R.; Pays, E. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422, 83-87.
74. Xong, H. V.; Vanhamme, L.; Chamekh, M.; Chimfwembe, C. E. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell. 1998, 95, 839-846.
75. Baral, T. N.; Magez, S.; Stijlemans, B.; Conrath, K.; Vanhollebeke, B.; Pays, E.; Muyldermans, S.; De Baetselier, P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated Human Trypanolitic Factor. Nat. Med. 2006, 12, 580-584.
76. Pays, E.; Vanhamme, L.; Perez-Morga, D.Antigenic variation in Trypanosoma brucei: facts, challenges and mysteries. Curr. Opin. Microbiol. 2004, 7, 369-374.
77. Horn, D. The molecular control of antigenic variation in Trypanosoma brucei. Curr. Mol. Med. 2004, 4, 563-576.
78. D'Silva, C.; Daunes, S. Structure-Activity Study on the in Vitro Antiprotozoal Activity of Glutathione Derivatives. J. Med. Chem. 2000, 43, 2072-2078.
79. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5, 471-484.
80. Klinman, D. M.; Verthelyi, D.; Takeshita, F.; Ishii, K. J. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity, 1999, 11, 123-129.
81. Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004, 4, 249-258.
82. Agrawal, S.; Kandimalla, E. R. Antisense and siRNA as agonists to Toll-like receptors. Nat. Biotechnol. 2004, 22, 1533-1537.
83. Grajkowski, A.; Pedras-Vasconcelos, J.; Wang, V.; Ausín, C.; Hess, S.; Verthelvi, D.; Beaucage, S. L. Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs. Nucleic Acids Res. 2005, 33, 3550-3560.
84. Verthelyi, D.; Ishii, K. J.; Gursel, M.; Takeshita, F.; Klinman, D. M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 2001, 166, 2372-2377
85. Verthelyi, D.; Kenney, R. T.; Seder, R. A.; Gam, A. A.; Friedag, B.; Klinman, D. M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 2002, 168, 1659-1663.
86. Verthelyi, D.; Gursel, M.; Kenney, R. T.; Lifson, J. D.; Shuying, L.; Mican, J.; Klinman, D. M. CpG Oligodeoxynucleotides protect normal and SIV infected macaques from Leishmania infection. J. Immunol. 2003, 170, 4717-4723.
87. Guiducci, C.; Ott, G.; Chan, J. H.; Damon, E.; Calacsan, C.; Matray, T.; Lee, K. D.; Coffman, R. L.; Barrat, F. J. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 2006, 203, 1999-2008.
88. Wu, C. C. N.; Lee, J.; Raz, E.; Corr, M.; Carson, D. Necessity of oligonucleotide aggregation for Toll-like receptor 9 activation. J. Biol. Chem. 2004, 279, 33071-33078.
89. Kerkmann, M.; Costa, L. T.; Richter, C.; Rothenfusser, S.; Battiany, J.; Hornung, V.; Johnson, J.; Englert, S.; Ketterer, T.; Heckl, W.; Thalhammer, S.; Endres, S.; Hartmann, G. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-{alpha} induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 2005, 280, 8086-8093.
90. Puig, M.; Grajkowski, A.; Bockowska, M.; Ausín, C.; Beaucage, S. L.; Verthelvi, D. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleics Acid Res. 2006, 34, 6488-6495.
91. Mansour, N. S.; Mcconnel, E. Leishmaniasis in the Sudan Republic 27. Lack of effect of chloroquine and pyrimethamine on visceral Leishmaniasis in the hamster. Am. J. Trop. Med. Hyg. 1966, 15, 146-148.
92. Bello, A. R.; Nare. B.; Freedman, D.; Hardy, L.; Beverley, S. M. PTR1: A reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc. Natl. Acad. Sci. USA. 1994, 9, 11442-11446.
93. Nare, B.; Hardy, L. W.; Beverley, S. M. The roles of pteridine reductase 1 and dihydrofolate reductasethymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J. Biol. Chem. 1997, 272, 13883-13891.
94. De Carvalho, P. B.; Ramos, D. C. C.; Cotrim, P. C.; Ferreira, E. I. Synthesis and in vitro evaluation of potential anti-leishmanial targeted drugs of pyrimethamine. J. Pharm. Sci. 2003, 92, 2109-2116.
95. Molyneux, D. H.; Ashford, R. W., Eds. The biology of Trypanosoma and Leishmania, parasites of man and domestic animals. International Publications: New York, 1983; pp. 211-249.
96. Chakraborty, R.; Chakraborty, P.; Basu, M. K. Macrophage mannosyl fucosyl receptor: Its role in invasion of virulent and avirulent L. donovani promastigotes. Biosci. Rep. 1998, 18, 129-142.
97. Croft, S. L.; Hogg, J.; Gutteridge, W. E.; Hudson, A. T.; Randall, A. W. The activity of hydroxynaphthoquinones against Leishmania donovani. J. Antimicrob. Chem. 1992, 30, 827-832.
98. Mäntylä, A.; Garnier, T.; Rautio, J.; Nevalainen, T.; Vepsälainen, J.; Koskinen, A.; Croft, S. L.; Järvinen, T. Synthesis, in vitro evaluation and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem. 2003, 47, 188-195.
99. Mäntylä, A.; Rautio, J.; Nevalainen, T.; Vepsälainen, J.; Juvonen, R.; Kendrick, H.; Garnier, T.; Croft, S.L.; Järvinen, T. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg. Med. Chem. 2004, 12, 3497-3502.
100. Mäntylä, A.; Garnier, T.; Rautio, J.; Nevalainen, T.; Vepsälainen, J.; Koskinen, A.; Croft, S. L.; Järvinent, T. Synthesis, in Vitro Evaluation, and Antileishmanial Activity of Water-Soluble Prodrugs of Buparvaquone. J. Med. Chem. 2004, 47, 188-195.
101. Fleisher, D.; Bong, R.; Stewart, B. H. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Delivery Rev. 1996, 19, 115-130.
102. Varia, S. A.; Schuller, S.; Sloan, K. B.; Stella, V. J. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 1984, 73, 1068-1073.
103. Krise, J. P.; Zygmunt, J.; Georg, G. I.; Stella, V. J. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of n-phosphonooxymethyl prodrugs. J. Med. Chem. 1999, 42, 3094-3100.
104. Garnier, T.; Mäntylä, A.; Järvinen, T.; Lawrence, J.; Brown, M.; Croft, S. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother. 2007, 60, 802-810.
105. Mäntylä, A.; Rautio, J.; Nevalainen, T.; Keski-Rahkonen, P.; Vepsälainen, J.; Järvinen, T. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. Eur. J. Pharm. Sci. 2004, 23, 151-158.
106. Jousserandot, A.; Boucher, J. L.; Henry, Y.; Niklaus, B.; Clement, B.; Mansuy, D. Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes, and ketoximes: mechanism of the oxidative cleavage of their C=N(OH) bond with formation of nitrogen oxides. Biochemistry 1998, 37, 17179-17191.
107. Chattopadhyay, R.; Mahajan, B.; Kumar, S. Assessment of safety of the major antimalarial drugs. Expert Opin Drug Saf. 2007, 6, 505-21.
108. Ferreira, E. I.; Cruz, M. L.; Korolkovas, A. Latentiation of chemotherapeutic agents. Part 1: synthesis of oxidized starch imine derivatives and antimalarials. Starch/starke 1992, 44, 21-24.
109. Ohara, M. T.; Sakuda, T. M.; Cruz, M. L.; Ferreira, E. I.; Korolkovas, A. Antimalarial Activity Of Imine Oxidized Starch And Cellulose Derivatives. Boll. Chim. Farm. 1995, 9, 522-527.
110. Cruz, M. L.; Ferreira, E. I.; Korolkovas, A. Latentiation of chemotherapeutic agents. Part 2: synthesis of oxidized cellulose imine derivatives and antimalarials. Starch/Stärke 1997, 49, 66-70.
111. Van Deenen, L. L. M.; De Gier, J. Lipids of the red cell membrane. In The red blood cell. Surgenor, G., (ed.); Academic Press, Inc.: New York, N.Y., 1975; pp. 147-211.
112. Nicolas, O.; Margout, N. T.; Wein, S.; Calas, M.; Vial, H. J.; Bressollei, F. M. Pharmacological Properties of a New Antimalarial Bisthiazolium Salt, T3, and a Corresponding Prodrug, TE3. Antimicrob. Agents Chemother. 2005, 49, 3631-3639.
113. Vial, H.J.; Wein, S.; Farenc, C.; Kocken, C.; Nicolas, O.; Ancelin, M. L.; Bressolles, F.; Thomas, A.; Calas, M. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15458-15463.
114. Calas, M..; Ancelin, M. L.; Cordina, G.; Portefaix, P.; Piquet, G.; Vidal-Sailhan, V.; Vial, H. Antimalarial Activity of Compounds Interfering with Plasmodium falciparum Phospholipid Metabolism: Comparison between Mono- and Bisquaternary Ammonium Salts. J. Med. Chem., 2000, 43, 505-516.
115. Wiesner, J.; Hintz, M.; Altincicek, B.; Sanderbrand, S.; Weidemeyer, C.; Beck, E.; Jomaa, H. Plasmodium falciparum: Detection of the Deoxyxylulose 5-Phosphate Reductoisomerase Activity. Exp. Parasitol. 2000, 96, 182-186.
116. Lell, B.; Ruangweerayut, R.; Wiesner, J.; Missinou, M. A.; Schindler, A.; Baranek, T.; Hintz, M.; Hutchinson, D.; Jomaa, H.; Kremsner, P. G. Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria. Antimicrob. Agents Chemother. 2003, 47, 735-738.
117. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs. Science. 1999, 285, 1573-1576.
118. Tsuchiya, T.; Ishibashi, K.; Terakawa, M.; Nishiyama, M.; Itoh, N.; Noguchi, H. Eur. J. Drug Metab. Pharmacokinet. Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs. 1982, 7, 59-64.
119. Reichenberg, A.; Wiesner, J.; Weidemeyer, C.; Dreiseidler, E.; Sanderbrand, S.; Altincicek, B.; Beck, E.; Schlitzer, M.; Jomaa, H. Diaryl Ester Prodrugs of FR900098 with Improved In Vivo Antimalarial Activity. Bioorg. Med. Chem. Lett. 2001, 11, 833-835.
120. Ortmann, R.; Wiesner, J.; Reichenberg, A.; Henscker, D.; Beck, E.; Jomaa, H.; Schlitzer, M. Acyloxyalkyl ester prodrugs of fr900098 with improved in vivo anti-malarial activity. Bioorg. Med. Chem. Lett. 2003, 13, 2163-2166.
121. Ortmann, R.; Wiesner, J.; Reichenberg, A.; Henschker, E. B.; Jomaa, H.; Schlitzer, M. Alkoxycarbonyloxyethyl Ester Prodrugs of FR900098 with Improved In Vivo Antimalarial Activity. Arch. Pharm. Chem. Life. Sci. 2005, 338, 305-314.
122. Hindley, S.; Ward, S. A.; Storr, R. C.; Searle, N. L.; Bray, P. G.; Park, K.; Davies, J.; O'Neil, P. M. Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of New Diamine Containing Analogues J. Med. Chem. 2002, 45, 1052-1063.
123. O'Neil, P.; Posner, G. H. A Medicinal Chemistry Perspective on Artemisinin and Related Endoperoxides. J. Med. Chem. 2004, 47, 2945-2964.
124. Borstnik, K.; Paik, I-H.; Posner, G. H. Malaria: New Chemotherapeutic Peroxide Drugs. Mini Rev. Med. Chem. 2002, 2, 573-583.
125. Cumming, J. N.; Ploypradith, P.; Posner, G. H. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv. Pharmacol. 1997, 37, 253-297.
126. O'Neil, P.; Stocks, P. A.; Pugh, M. D.; Araujo, N. C.; Korshin, E.; Bickley, J. F.; Ward, S. A.; Bray, P. G.; Pasini, E.; Davies, J.; Verissimo, E.; Bach, M. D. Design and Synthesis of Endoperoxide Antimalarial Prodrug Models. Angew. Chem. 2004, 43, 4193-4197.
127. Jefford, A. W. Why Artemisinin and Certain Synthetic Peroxides are Potent Antimalarials. Implications for the Mode of Action. Curr. Med. Chem. 2001, 8, 1803-1826.
128. Eckstein-Ludwig, U.; Webb, R. J.; van Goethem, I. D. A.; East, J. M.; Lee, A. G.; Kimura, M.; O'Neil, P. M.; Bray, P. G.; Ward, s. A.; Krishna S. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424, 957-961.
129. Li, R.; Kenyon, G. L.; Cohen, F. E.; Chen, X.; Gong, B.; Dominguez, J. N.; Davidson, E.; Kurzban, G.; Miller, R. E.; Nuzum, E. O.; Rosenthal, P. J.; McKerrol, J. H. In Vitro Antimalarial Activity of Chalcones and Their Derivatives. J. Med. Chem. 1995, 38, 5031-5037.
130. Atamna, H.; Ginsburg, H. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells J. Biol. Chem. 1995, 270, 24876-24883.
131. Schirmer, R. H.; Müller, J. G.; Krauth-Siegel, R. L. Disulfide reductase inhibitors as chemotherapeutic agents: the design of drugs for trypanosomiasis and malaria Angew. Chem. Int. Edn. 1995, 34, 141-154.
132. Davioud-Charvet, E.; Delarue, S.; Biot, C.; Schwobel, B.; Boehme, C. C.; Mussigbrodt, A.; Maes, L.; Sergheraert, C., Grellier, P.; Schirmer, R. H., Becker K. A prodrug for of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem. 2001, 44, 4268-4276.
133. Meierjohann, S.; Walter, R. D.; Muller, S. Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem. J. 2002, 368, 761-768.
134. Biot, C.; Dessolin, J.; Grellier, P.; Davioud-Charvet, E. Double-drug development against antioxidant enzymes from Plasmodium falciprurn. Redox Rep. 2003, 8, 280-283.
135. Gomes, P.; Araujo, M. J.; Rodriguez, M.; Vale, N.; Azevedo, Z.; Iley, J.; Chambel, P.; Morais, J.; Moreira, R. Synthesis of imidazolidin-4-one and 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione derivatives of primaquine: scope and limitations. Tetrahedron. 2004, 60, 5551-5562.
136. Brueckner, R. P.; Ohrt, C.; Baird, J. K.; Milhous, W. K. In Antimalarial Chemotherapy; Rosenthal, P. J., Ed.; Humana: Totowa, 2001; pp. 123-151.
137. Trouet, A.; Pirson, P.; Steiger, R.; Masquelier, M.; Baurain, R.; Gillet, J. Development of new derivatives of primaquine by association with lysosomotropyc carriers. Bull. World Health Org. 1981, 59, 449-458.
138. Philip, A.; Kepler, J A.; Johnson, B. H.; Carroll, F. I. Peptide Derivatives of Primaquine as Potential Antimalarial Agents. J. Med. Chem. 1988, 31, 870-874.
139. Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aube, J.; Borchardt, R. T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug. Del. Rev. 1997, 27, 235-256.
140. Bundgaard, H. (C) Means to enhance penetration: (1) Prodrugs as a means to improve the delivery of peptide drugs. Adv. Drug. Del. Rev. 1992, 8, 1-38.
141. Borissova, R.; Stjarnkvist, P.; Karlsson, M. O.; Sjoholm, I. Biodegradable microspheres. 17. Lysosomal degradation of primaquine-peptide spacer arms. J. Pharm. Sci. 1995, 84, 256-262.
142. Portela, M. J.; Moreira, R.; Valente, E.; Constantino, L.; Iley, J.; Pinto, J.; Rosa, R.; Cravo, P.; do Rosario, V. E. Dipeptide Derivatives of Primaquine as Transmission-Blocking Antimalarials: Effect of Aliphatic Side-Chain Acylation on the Gametocytocidal Activity and on the Formation of Carboxyprimaquine in Rat Liver Homogenates. Pharm. Res. 1999, 16, 949-955.
143. Bak, A.; Fich, M.; Larsen, B. D.; Frokjaer, S.; Friis, G. J. N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin: synthesis, chemical and enzymatic stability studies. Eur. J. Pharm. Sci. 1999, 7, 317-323.
144. Araujo, M.. J.; Bom, J.; Capela, R.; Casimiro, C.; Chambel, P.; Gomes, P.; Iley, J.; Lopes, F.; Morais, J.; Moreira, R.; de Oliveira, E.; do Rosario, V.; Vale, N. Imidazolidin-4-one Derivatives of Primaquine as Novel Transmission-Blocking Antimalarials. J. Med. Chem. 2005, 48, 888-892.
145. Vagapandu, S.; Sachdeva, S.; Jain, M.; Singh, S.; Singh, P. P.; Kaul, C. L.; Jain, R. 8-Quinolinamines and Their Pro Prodrug Conjugates as Potent Blood-Schizontocidal Antimalarial Agents. Bioorg. Med. Chem. 2003, 11, 4557-4568.
146. Goldberg, D. E.; Slater, A. F.; Beavis, R.; Chait, B.; Cerami, A.; Henderson, G. Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 1991, 173, 961-969.
147. Romeo, S.; Dell'Agli, M.; Parapini, S.; Rizzi, L.; Galli, G.; Mondani, M.; Sparatore, A.; Taramelli, D.; Bosisio, E. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'. Bioorg. Med. Chem. Lett. 2004, 14, 2931-2934.
148. Yuthavong, Y. Basis for antifolate action and resistance in malaria. Microbes Infect. 2002, 4, 175-182.
149. Rieckmann, K. H. The in vitro activity of experimental antimalarial compounds against strains of Plasmodium falciparum with varying degrees of sensitivity to pyrimethamine and chloroquine. In Chemotherapy of malaria and resistance to antimalarials (World Health Organization Technical Report Series); World Health Organization: Geneva, Switzerland, 1973; p. 58.
150. Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M. D.; Yuthavong, Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 2003, 10, 357-365.
151. Rieckmann, K. H.; Yeo, A. E.; Edstein, M. D. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo-in vitro model. Trans. R. Soc. Trop. Med. Hyg. 1996, 90, 568-571.
152. Canfield, C. J.; Milhous, W. K.; Ager, A. L.; Rossan, R. N.; Sweeney, T. R. Lewis, N. J.; Jacobus, D. P. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. J. Trop. Med. Hyg. 1993, 49, 121-126.
153. Shearer, T. W.; Kozar, M. P.; O'Neil, M. T.; Smith, P. L.; Schiehser, G. A.; Jacobus, D. P.; Diaz, D. S.; Yang, Y-S.; Milhous, W. k.; Skillman, D. R. In Vitro Metabolism of Phenoxypropoxybiguanide Analogues in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines. J. Med. Chem. 2005, 48, 2805-2813.
154. Wiesner, J.; Kettler, K.; Sakowski, J.; Ortmann, R.; Katzin, A. M.; Kimura, E. A.; Silber, K.; Klebe, G.; Jomaa, H.; Schlitzer, M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew. Chem., Int. Ed. 2004, 43, 251-254.
155. Casey, P. J.; Seabra, M. C. Protein Prenyltransferases. J. Biol. Chem. 1996, 271, 5289-5292.
156. Ohkanda, J.; Lockman, J. W.; Yokoyama, K.; Gelb, M. H.; Croft, S. L.; Kendrick, H.; Harrell, M. I.; Feagin, J. E.; Blaskovich, M. A.; Sebti, S. M.; Hamilton, A. D. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg. Med. Chem. Lett. 2001, 11, 761-764.
157. Carrico, D.; Ohkanda, J.; Kendrick, H.; Yokoyama, K.; Blasklovich, M. A.; Bucher, C. J.; Buckner, F. S.; van Voorhis, W. C.; Chakrabarti, D.; Croft, S.; Gelb, M. H.; Sebti, S. M.; Hamilton, A. D. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg. Med. Chem. 2004, 12, 6517-6526.
158. Ledig, K. W. 7-(Substituted)-7H-pyrrolo[3,2,-f]quinazoline-1,3-diamines. U.S. Patent 4,118,561, 1978.
159. Davoll, J.; Johnson, A. M.; Davies, H. J.; Bird, O. D.; Clarke, J.; Elslager,. E. F. Folate antagonists. 2. 2,4-Diamino-6-((aralkyl and (heterocyclic) methyl)amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease. J. Med. Chem. 1972, 15, 812-826.
160. Elslager, E. F.; Bird, O. D.; Clarke, J.; Perricone, S. C.; Worth, D. F. Folate antagonists. 9. 2,4-Diamino-6-((aralkyl)alkylamino)quinazolines, a potent class of antimetabolites with prodigious antimalarial effects. J. Med. Chem. 1972, 15, 1138-1146.
161. Hua, H.; Cheng, M.; Li, X.; Pei, Y. A new pyrroloquinazoline alkaloid from Linaria vulgaris. Chem. Pharm. Bull. 2002, 50, 1393-1394.
162. Guan, J.; Zhang, Q.; O'Neil, M.; Obaldia III, N.; Ager, A.; Gerena, L.;
163. Xie, L. H.; Li, Q.; Lin, A. J.; Smith, K.; Zhang, J.; Skillman, D. New Potential Antimalarial Agents: Therapeutic-Index Evaluation of Pyrroloquinazolinediamine and Its Prodrugs in a Rat Model of Severe Malaria. Antimicrob. Agents Chemother. 2006, 50, 1649-1655.
164. Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996, 39, 3139-3147.
165. Zhou, L.; Lee, K.; Thakker, D. R.; Boykin, D. W.; Tiwell, R. R.; Hall, J. E. Enhanced Permeability of the Antimicrobial Agent 2,5-Bis(4-Amidinophenyl) Furan Across Caco-2 Cell Monolayers Via Its Methylamidoxime Prodrug. Pharm. Res. 2002, 19, 1689-1685.
166. Kitamura, S. F. H.; Miyawaki, T.; Kawamura, M.; Terashita, Z-I.; Naka, T. Orally Active GPIIb/IIIa Antagonists: Synthesis and Biological Activities of Masked Amidines as Prodrugs of 2-[(3S)-4-[(2S)-2-(4- Amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl) -2-oxopiperazinyl]acetic Acid. Chem. Pharm. Bull. 2001, 49, 268-277.
167. Rehse, K.; Bade, S.; Harsdorf, A.; Clement, B. New NO-Donors with Antithrombotic and Vasodilating Activities, Part 17. Arylazoamidoximes and 3-Arylazo-1,2,4-oxadiazol-5-ones. Arch. Pharm. 1997, 330, 392-398.
168. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs Bioorg. Med. Chem. Lett. 1996, 6, 3017-3020.
169. Berger, B. J.; Lombardy, R. J.; Marbury, G. D.; Bell, C. A.; Dykstra, C. C.; Hall, J. E.; Tidwell, R. R. Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob. Agents Chemother. 1990, 34, 1678-1684.
170. 2-insensitive NADH-Benzamidoxime Reductase. J. Biol. Chem. 1997, 272, 19615-19620.
171. Outtara, M.; Wein, S.; Calas, M.; Hoang, Y. V.; Vial, H.; Escale, R. Synthesis and antimalarial activity of new 1,12-bis- (N,N)-acetamidinyl)dodecane derivatives Bioorg. Med. Chem. Lett. 2007, 17, 593-596.
172. Cerami, C.; Frevert, U.; Sinnis, P.; Takacs, B.; Clavijo, P.; Santos, M. J.; Nussenzweig, V. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell. 1992, 70, 1021-1033.
173. Ding, Z. M.; Cristiano, R. J.; Roth, J. A.; Takacs, B.; Kuo, M. T. Malarial circumsporozoite protein is a novel gene delivery vehicle to primary hepatocyte cultures and cultured. J. Biol. Chem. 1995, 270, 3667-3676.
174. Lin-Lee, Y-C.; Nakamura, S.; Gandhi, V.; Curley, S. A.; Stüber, D.; Burkot, T. R.; Kuo, M. T. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol. Cancer Ther. 2002, 1, 461-467.
175. Nussenzweig, V. Malaria sporozoites and chylomicron remnants compete for binding sites in the liver. Behring Inst. Mitt. 1997, 99, 85-89.
176. Parise Filho, R.; Menezes, C.M.S.; Pinto, P.L.S.; Paula, G.A.; Brandt, C.A.; Siveira, M.A.B. Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Bioorg. Med. Chem. 2007, 15, 1229-1236.
177. Almeida, A.E.; Ferreira, A.G.; Crespi, M.S.; Andrade, Z.A.; Man-Chin, C. Synthesis and thermal study of prodrug of oxamniquine. J. Therm. Anal. Cal., 2006, 83, 277-281.
178. El-Hamouly, W.; Pica-Mattocia, L.; Cioli, D.; Schwartz, H.M.; Archer, S. Studies on some derivatives of oxamniquine. J. Med. Chem. 1988, 31, 1629-1631.
179. Shaohong, L.; Kumagai, T.; Qinghua, A., Xiaolan, Y.; Ohmae, H.; Yabu, Y.; Siwen, L.; Liyong, W.; Maruyama, H.; Ohta, N. Evaluation of the anthelmintic effects of artesunate against experimental Schistosoma mansoni infection in mice using different treatment protocols. Parasitol. Int. 2006, 55, 63-68
180. Utzinger, J.; Chollet, J.; Tu, Z.; Shuhua,X.; Tanner, M. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans. R. Soc. Trop. Med. Hy. 2002, 96, 318-323.
181. Jiraungkoorskul, W.; Sahaphong, S.; Sobhon, P.; Riengrojpitak, S.; Kangwanrangsan, N. Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice. Parasitol. Int. 2005, 54, 177-183.
182. Zhang, Y.; Scorpio, A.; Nikaido, H. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 1999, 181, 2044-9.
183. Zhang, Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 529-64.
184. Scorpio, A.; Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 1996, 2, 662-667.
185. Hanoulle, X.; Wieruszeski, J-M.; Rousselot-Pailley, P.; Landrieu, I.; Locht, C.; Lippens, G.; Baulard, A. R. Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J. Antimicrob. Chemother. 2006, 58, 768-772.
186. DeBarber, A. E.; Mdluli, K.; Bosman, M.; Bekker, L. G.; Barry III, C. E. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9677-9682.
187. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992, 358, 591-593.
188. Heym, B.; Zhang, Y.; Poulet, S.; Young, D.; Cole, S. T. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J. Bacteriol. 1993, 175, 4255-4259.
189. Ghiladi, R. A.; Medzihardsky, K. F.; Rusnak, F. M.; de Montellano, P. R. O. Correlation between isoniazid resistance and superoxide reactivity in mycobacterium tuberculosis katg. J. Am. Chem. Soc. 2005, 127, 13428-13442.
190. Vannelli, T. A.; Dykman, A.; de Montellano, P. R. O. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 2002, 277, 12824-12829.
191. Fraaije, M. W.; Kamerbeek, N. M.; Heidekamp, A. J.; Fortin, R.; Janssen, D. B. The prodrug activator etaa from Mycobacterium tuberculosis is a baeyer-villiger monooxygenase. J. Biol. Chem. 2004, 279, 3354-3360.
192. Baulard, A. R.; Betts, J. C.; Engohang-Ndong, J.; Quan, S.; McAdam, R. A.; Brennan, P. J.; Locht, C.; Besra, G. S. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 2000, 275, 28326-28331.
193. Phetsuksiri, B.; Baulard, A. R.; Cooper, A. M.; Minnikin, D. E.; Douglas, J. D.; Besra, G. S.; Brennan, P. J. Antimycobacterial Activities of Isoxyl and New Derivatives through the Inhibition of Mycolic Acid Synthesis. Antimicrob. Agents Chemother. 1999, 43, 1042-1051.
194. Qian, L; de Montellano, P. R. O. Oxidative activation of thiacetazone by the mycobacterium tuberculosis flavin monooxygenase etaa and human fmo1 and fmo3. Chem. Res. Toxicol. 2006, 19, 443-449.
195. Kathleen, P. Martindale: The Complete Drug Reference, 32nd Edn.; Pharmaceutical Press: Chicago, USA, 1999; p. 151.
196. Byrd, R. B.; Horn, B. R.; Solomon, D. A.; Griggs, G. W. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA. 1979, 241, 1239-1241.
197. Miller, R. R.; Porter, J.; Greenblatt, D. J. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. Chest. 1979, 75, 356-8.
198. Prateek, J. R.; Jaim, K.; Ravichandran, V.; Agrawal, R. K. Synthesis and evaluation of mutual prodrugs of isoniazid, p-amino salicylic acid and ethambutol. Arkivoc 2007, 1, 105-118.
199. Wayne, L. G. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, 908-914.
200. Wayne, L. G.; Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 1996, 64, 2062-2069.
201. Samuelson, J. Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother. 1999, 43, 1533-1541.
202. Brooks, J. V.; Furney, S. K.; Orme, I. M. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 1999, 43, 1285-1288.
203. Lenaerts, A. J.; Gruppo, V.; Marietta, K. S.; Johnson, C. M.; Driscoll, D. K.; Tompkins, N. M.; Rose, J. D.; Reynolds, R. C.; Orme, I. M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 2005, 49, 2294-2301.
204. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 2006, 103, 431-436.
205. Stover, C. K.; Warrener, P.; Vandevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405, 962-966.
206. Papadopoulou, M. V.; Bloomer, W. D.; McNeil, M. R. NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents. 2007, 29, 724-727.
207. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 2000, 12,185-192.
208. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol. Res. 2003, 14, 21-29.
209. Sriram, D.; Yogeeswari, P. Towards the design and development of agents with broad spectrum chemotherapeutic properties for the effective treatment of HIV / AIDS. Curr. Med. Chem. 2003, 10, 1909-1915.
210. Sriram, D.; Yogeeswari, P.; Narasimharaghavan, S.; Bai, T. R. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg. Med. Chem. Lett. 2004, 14, 1085-1087.
211. Sriram, D.; Bal, T. R.; Yogeeswari, P. Design, synthesis and biological evaluation of novel nonnucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Bioorg. Med. Chem. 2004, 12, 5865-5873.
212. Sriram, D.; Srichakravarthy, N.; Bal, T. R.; Yogeeswari, P. Dossier: HIV/AIDS: New approaches in chemotherapy and Immunotherapy. Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Biomed. Pharmacother. 2005, 59, 452-455.
213. Sriram, D.; Yogeeswari, P.; Gopal, G. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Eur. J. Med. Chem. 2005, 40, 1373-1376.
214. Steinberg, T. H. Cellular transport of drugs. Clin. Infect. Dis. 1994, 19, 916-921.
215. Donowitz, G. R. Tissue-directed antibiotics and intracellular parasites: complex interaction of phagocytes, pathogens, and drugs. Clin. Infect. Dis. 1994, 19, 926-930.
216. Gordon, S.; Rabinowitz, S. Macrophages as targets for drug delivery. Adv. Drug Deliv. Rev. 1989, 4, 27-47.
217. Roseeuw, E.; Coessens, V.; Balazuc, A-M.; Lagranderie, M.; Chavarot, P.; Pessina, A.; Néri, M. G.; Schacht, E.; Marchal, G.; Domurado, D. Synthesis, Degradation, and Antimicrobial Properties of Targeted Macromolecular Prodrugs of Norfloxacin. Antimicrob. Agents Chemother. 2003, 47, 3435-3441.
218. Roseeuw, E.; Coessens, V.; Schat, E.; Vrooman, B.; Domurado, D.; Marchal, G. Polymeric prodrugs of antibiotics with improved efficiency. J. Mater. Sci. Mater. Med. 1999, 10, 743-746.
219. Aubrée-Lecat, A., Duban, M-C.; Demignot, S.; Domurado, M.; Fournié, P.; Domurado. D. Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target. J. Pharmacokinet. Biopharm. 1993, 21, 75-98.
220. Balazuc, A. M.; Lagranderie, M.; Chavarot, P.; Pescher, P.; Roseeuw, E.; Schacht, E.; Domurado, D.; Marchal, G. In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver. Microbes Infect. 2005, 7, 969-975.
221. Silva, M. ; Lara, A. S. ; Leite, C. Q. F. ; Ferreira, E. I. . Potential tuberculostatic agents: micelleforming copolymer poly(ethyleneglycol)- poly(aspartic acid) prodrug with isoniazid. Arch. Pharm. Pharm. Med. Chem. 2001, 334, 189-193.
222. Silva, M.; Ricelli, N. L.; Seoud, O. E.; Valentim, C. S.; Ferreira, A.; Sato, D. N.; Leite, C. Q. F.; Ferreira, E. I. Potential Tuberculostatic Agent: Micelle-forming Pyrazinamide Prodrug. Arch. Pharm. Chem. Life Sci. 2006, 339, 283-290.
223. Yokoyama, M.; Miyauchi, M.; Yamada, N.; Okano, T.; Sakurai, Y.; Kataoka, K.; Inoue, S. Polymer micelles as novel drug carriers: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. In Advances in Drug Delivery Systems; Anderson, J. M., Kim, S. W.; Knutson, K.; Eds.: Elsevier: Amsterdam, 1990;Vol. 4, pp. 269-278.
224. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki, M.; Matsumura, Y.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Development of the polymer micelle carrier system for doxorubicin. J. Control Release. 2001, 74, 295-302.
225. Rando, D. G. ; Brandt, C. A. ; Ferreira, E. I. Use of N-methylene phosphonic chitosan to obtain an isoniazid prodrug. Rev. Bras. Ciên. Farm. 2004, 40, 335-344.
226. Shibata, Y.; Metzger, W. J.; Myrvik, Q. N. Chitin particle-induced cell- mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol. 1997, 159, 2462-2467.
227. Heras, A,; Rodríguez, N.M.; Ramos, V.M.; Agulló, E. N-methylene phosphonic chitosan: a novel soluble derivative. Carbohydr. Polym. 2001, 44, 1-8.
228. Jones, R. N.; Ross, J. E.; Fritsche, T. R.; Sader, H. S. J. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations. Antimicrob. Chemother. 2006, 57, 279-287.
229. Vera-Cabrera, L.; Ochoa-Felix, E. Y.; Gonzalez, G.; Tijerina, R.; Choi, S. H.; Welsh, O. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae. Antimicrob. Agents Chemother. 2004, 48, 1037-1039.
230. Vera-Cabrera, L.; Castro-Garza, J.; Rendon, A.; Ocampo-Candiani, J.; Welsh, O.; Choi, S. H.; Blackwood, K.; Molina-Torres, C. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob. Agents Chemother. 2005, 49, 4351-4353.
231. Vera-Cabrera, L.; Gonzalez, E.; Choi, S. H.; Welsh; O. In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob. Agents Chemother. 2004, 48, 602-604.
232. Gomez-Flores, A.; Welsh, O.; Said-Fernandez, S.; Lozano-Garza, G.; Tavarez-Alejandro, R. E.; Vera-Cabrera, L. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob. Agents Chemother. 2004, 48, 832-837.
233. Fortun, J.; Martin-Davila, P.; Navas, E.; Perez-Elias, M. J.; Cobo, J.; Tato, M.; De la Pedrosa, E. G.; Gomez-Mampaso, E.; Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 2005, 56, 180-185.
234. Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs. 1999, 8, 1195-1202.
235. Vera-Cabrera, L.; Gonzalez, E.; Rendon, A.; Ocampo-Candiani, J.; Welsh, O.; Velazquez-Moreno, V. M.; Choi, S. H.; Molina-Torres, C. In Vitro Activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother. 2006, 50, 3170-3172.
236. Cummings, J.H. Short chain fatty acids in the human colon. Gut 1981, 22, 763-779.
237. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem. 1982, 42, 65-82.
238. Nudelman, A.; Gnizi, E.; Katz, Y.; Azulai, R.; Cohen-Ohana, M.; Zhuk, R.; Sampson, S.R.; Langzam, L.; Fibach, E.; Prus, E.; Pugach, V.; Rephaeli, A. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur. J. Med. Chem. 2001, 36, 63-74.
239. Dover, G.J.; Brusilow, S.; Samid, D. Increased fetal hemoglobin in patients receiving sodium 4-Phenylbutyrate. New Engl. J. Med. 1992, 327, 569-570.
240. Charache, S.; Terrin, M.L.; Moore, R.D.; Dover, G.J.; Barton, F.B.; Eckert, S.V.; McMahon, R.P.; Bonds, D.R. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia N. Engl. J. Med. 1995, 332, 1317-1322.
241. Atweh, G.F.; Sutton, M.; Nassif, I.; Boosalis, V.; Dover, G.J.; Wallenstei, S.; Wright, E.; McMahon, L.; Stamatoyannopoulos, G.; Faller, D.V.; Perrine, S.P. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999, 93, 1790-1797.
242. Safo, M.K.; Abdulmalik, O.; Danso-Danquat, R.; Burnett, J.C.; Nokuri, S.; Joshi, G.S.; Musayev, F.N.; Asakura, T.; Abraham, D.J. Structural basis for the potent antisickiling effects of a novel class of five membered heterocyclic aldehydic compounds. J. Med. Chem. 2004, 47, 4665-4676
243. Zaugg, R.H.; Walder, J.A.; Klotz, I.M. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. J. Biol. Chem. 1977, 252, 8542-8548.
244. Abraham, D.J.; Mehanna, A.S.; Wireko, F.C.; Whitney, J.; Thomas, R.P.; Orringer, E.P. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood. 1991, 77, 1334-1341.
245. Safo, M,K.; Danso-Danquat, R.; Joshi, G.S.; Abraham, D.J. Antisickling agents. US2005/0209199 A1, 2005.
246. Zhang, C.; Li, X.; Lian, L.; Chen, Q.; Abdulmalik, O.; Vassilev, V.; Lai, C.S.; Asakura, T.; Antisickling effect of MX-1520, a prodrug of vanillin: an in vivo study using rodents. Br. J. Haematol. 2004, 125, 788-795.
247. Yarbro, J.M. Mechanism of action oh hydroxyurea. Semin. Oncol. 1992, 19, 1-10.
248. Hanft, V.N.; Fruchtman, S.R.; Pickens, C.V.; Rosse, W.F.; Howard, T.A.; Ware, R.E. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000, 95, 3589-3593.
249. Steinberg, M.H.; Barton, F.; Castro, O.; Pegelow, C.H.; Balas, S.K.; Kutlar, A.; Orringer, E.; Bellevie, R.; Olivieri, N.; Eckman, J.; Varma, M.; Ramirez, G.; Adler, B.; Smith, W.; Carlos, T.; Ataga, K.; Decastro, L.; Bjelow, C.; Sauntharajah, Y.; Telfer, M.; Bonds, D.; Terrin, M. Effect Of Hydroxyurea On Mortality And Morbidity In Adult Sickle Cell anemia: risks and benefits up to nine years of treatment. JAMA 2003, 289, 1645-1651.
250. Charache, S.; Barton, F.B.; Moore, R.D.; Terrin, M.L.; Steinberg, M.H.; Dover, G.J.; Ballas, S.K.; Mcmahon, R.P.; Castro, O.; Orringer, E.P. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 1996, 75, 300-326.
251. Space, S.L.; Lane, P.A.; Pickett, C.K.; Weil, J.L. nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am. J. Hematol. 2000, 63, 200-204.
252. Conran, N.; Oresco-Santos, C.; Acosta, H.C.; Fattori, A.; Saad, S.T.; Costa, F.F. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br. J. Haematol. 2004, 124, 547-554.
253. Minamiyama, Y.; Takemura, S.; Hai, S.; Suehiro, S.; Okada, S.; Funae, Y. Nicorandil Elevates Tissue cGMP Levels in a Nitric-Oxide-Independent Manner. J. Pharmacol. Sci. 2007, 103, 33-39.
254. Cokic, V.P.; Smith, R.D.; Beleslin-cokic, B.B.; Njoroge, J.M.; Miller, J.L.; Gladwin, M.T.; Schechter, A.N. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 2003, 111, 231-239.
255. Unpublished results